AstraZeneca PLC (AZN) Analysts See $0.28 EPS as of May, 18

May 17, 2018 - By Andrea Bass

AstraZeneca PLC (NYSE:AZN) Corporate Logo

Investors expect AstraZeneca PLC (NYSE:AZN)’s quarterly earnings on May, 18 before the open., as reported by Faxor. This year’s EPS analyst estimate is expected to be $0.28. That is 71.72 % down compareed to $0.99 EPS for last year. AZN’s profit could hit $697.23M if the current EPS of $0.28 is accurate. After $1.30 EPS was reported last quarter, analysts now see negative EPS growth of -78.46 % for AstraZeneca PLC. The stock increased 0.72% or $0.26 during the last trading session, reaching $36.5.Currently AstraZeneca PLC is uptrending after 9.03% change in last May 17, 2017. AZN has 3.44 million shares volume. The stock underperformed the S&P 500 by 2.52%.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

In total 5 analysts cover AstraZeneca (NYSE:AZN). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. 80% are bullish. With $42.0 highest and $36.0 lowest target AstraZeneca has $40 average target or 9.59% above the current ($36.5) price. 6 are the (NYSE:AZN)’s analyst reports since December 29, 2017 according to StockzIntelligence Inc. On Monday, March 19 the stock of AstraZeneca PLC (NYSE:AZN) earned “Buy” rating by Jefferies. The company rating was maintained by Leerink Swann on Thursday, January 18. On Monday, February 5 the firm has “Buy” rating by Bernstein given. In Tuesday, February 6 report Leerink Swann maintained the stock with “Market Perform” rating. On Friday, December 29 the stock of AstraZeneca PLC (NYSE:AZN) earned “Buy” rating by J.P. Morgan. On Friday, December 29 the company was upgraded by JP Morgan.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.The company has $90.89 billion market cap. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.The P/E ratio is 30.8. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

A couple more AstraZeneca PLC (NYSE:AZN) news were brought out by: which released on May 16, 2018 “3 Dividend Stocks to Fund Your Nest Egg”, also on May 16, 2018 brought out “AstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion – Bloomberg”, the next is “AstraZeneca (AZN) PT Raised to $41 at BMO Capital” on May 15, 2018. has article titled “AstraZeneca Shares Are Looking Very Weak Right Now”.

AstraZeneca PLC (NYSE:AZN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: